A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Depressive Disorder and Anxiety Disorders

In brief

This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.

Key facts

Study ID

NCT00513565

Run by

GlaxoSmithKline

People needed

22

Starts

2007-09-13

Expected to finish

2009-05-14

Last updated by the study team

2017-07-21

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy males
• Non-smokers
• Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-29.9 kg/m2
• Normal ECG.

You may not qualify if…

• Any serious medical disorder or condition.
• Any history of an endocrine disorder.
• Any clinically significant laboratory abnormality.
• History of psychiatric illness.
• Any history of suicidal attempts or behavior.
• History or current diagnosis of acute narrow angle glaucoma.
• Left handed

Where it is running

• GSK Investigational Site — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.